Your browser doesn't support javascript.
loading
Increased expression of matrix metalloproteinases 2 and 9 as poor prognosis factor for Hodgkin's lymphoma patients
Silva, Bárbara de Oliveira; Medeiros, Jonathan Wagner; Albuquerque, Giwellington Silva; Valderrama, Pavel Medina; Barbosa, Athos Henrique de Quevedo; Souza, Juliana Maria de; Oliveira, Renata Santos; Morais, Adriana Lins; Silva Neto, Jacinto da Costa; Muniz, Maria Tereza Cartaxo.
  • Silva, Bárbara de Oliveira; Universidade de Pernambuco. Instituto de Ciências Biológicas. Recife. BR
  • Medeiros, Jonathan Wagner; Universidade de Pernambuco. Instituto de Ciências Biológicas. Recife. BR
  • Albuquerque, Giwellington Silva; Universidade de Pernambuco. Instituto de Ciências Biológicas. Recife. BR
  • Valderrama, Pavel Medina; Universidade de Pernambuco. Instituto de Ciências Biológicas. Recife. BR
  • Barbosa, Athos Henrique de Quevedo; Universidade Federal de Pernambuco. Departamento de Citopatologia. Recife. BR
  • Souza, Juliana Maria de; Universidade de Pernambuco. Instituto de Ciências Biológicas. Recife. BR
  • Oliveira, Renata Santos; Universidade de Pernambuco. Instituto de Ciências Biológicas. Recife. BR
  • Morais, Adriana Lins; Universidade Federal de Pernambuco. Hospital Universitário Oswaldo Cruz. Centro de Oncohematologia Pediátrica. Recife. BR
  • Silva Neto, Jacinto da Costa; Universidade Federal de Pernambuco. Departamento de Citopatologia. Recife. BR
  • Muniz, Maria Tereza Cartaxo; Universidade de Pernambuco. Instituto de Ciências Biológicas. Recife. BR
J. pediatr. (Rio J.) ; 99(1): 59-64, Jan.-Feb. 2023. tab, graf
Article in English | LILACS-Express | LILACS | ID: biblio-1422026
ABSTRACT
Abstract

Objective:

The aim of our study was to evaluate the expression of MMP-2 and MMP-9 as a prognostic factor in patients diagnosed with Hodgkin Lymphoma (HL).

Methods:

In the present study, 45 paraffin biopsies from patients up to 19 years old diagnosed with HL were used in two referral hospitals in the state of Pernambuco, Brazil. Risk groups were classified into favorable and unfavorable, according to Ann Arbor. The expression of matrix metalloproteinases 2 and 9 and their inhibitors was performed by immunohistochemistry (IHC). Data were analyzed using the GraphPad Prism 5 program.

Results:

MMP-2 intensity pattern was stronger (> 10% of the total field) in patients with stage III/ IV and B symptoms. MMP-2 showed an association with the risk group (p = 0.0388). That is, the stronger the MMP-2 marking, the greater the unfavorable risk. However, for MMP-9 there was no difference in the stronger intensity pattern in relation to stages I/II and III/IV, only in the presence of B symptoms. MMP-9 showed an association with B Symptoms (p = 0.0411). Therefore, patients with B symptoms have higher MMP-9 expression.

Conclusion:

Our results suggest that MMP-2 expression is associated with HL progression. While MMP-9 expression is related to the clinical worsening of these patients. However, further studies are needed to evaluate the exact role of these proteins in hematologic malignancies.


Full text: Available Index: LILACS (Americas) Type of study: Prognostic study / Risk factors Language: English Journal: J. pediatr. (Rio J.) Journal subject: Pediatrics Year: 2023 Type: Article / Project document Affiliation country: Brazil Institution/Affiliation country: Universidade Federal de Pernambuco/BR / Universidade de Pernambuco/BR

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Index: LILACS (Americas) Type of study: Prognostic study / Risk factors Language: English Journal: J. pediatr. (Rio J.) Journal subject: Pediatrics Year: 2023 Type: Article / Project document Affiliation country: Brazil Institution/Affiliation country: Universidade Federal de Pernambuco/BR / Universidade de Pernambuco/BR